Defence Therapeutics Announces AGM Results and Provides Corporate Updates

Corporate Governance - Defence Therapeutics Inc. held its annual general meeting where shareholders approved all matters presented, including setting the number of directors at five and electing the board members with 100% approval [1] Stock Options and Warrants - The company granted a total of 800,000 stock options to certain directors, officers, and employees, exercisable at a price of $0.82 per Class A Common share for a period of 10 years [2] - An amendment was made to the terms of 967,000 Common Share purchase warrants, extending the expiry date by 12 months and repricing the exercise price to $1.00 per Common Share [3] Marketing Engagement - Defence entered into a two-month online marketing agreement with i2i Marketing Group for a total cash consideration of USD$300,000, with $50,000 paid upfront and the remainder contingent upon completion of conditions [4] Company Overview - Defence Therapeutics is a publicly-traded biotechnology company focused on engineering next-generation ADC products using its proprietary ACCUM® technology, which enhances the precision delivery of biologics to target cells, improving efficacy and market opportunities [6]